Acumen Pharmaceuticals (ABOS) investor relations material

Company overview and business model

• Clinical-stage biopharma focused on disease-modifying Alzheimer’s therapies targeting soluble amyloid-beta oligomers, which its research position identifies as a key driver of disease pathology.

• Lead candidate sabirnetug is a humanized monoclonal antibody designed to selectively target amyloid-beta oligomers; additional candidates ACU301 and ACU401 use JCR’s blood-brain-barrier-penetrating J-Brain Cargo technology.

• Development strategy spans IV sabirnetug, a potential subcutaneous formulation, and next-generation brain-delivery candidates; an IND application for the lead EBD candidate is targeted for mid-2027.

Financial performance and metrics

• Audited FY2025 financial statements include an auditor explanatory paragraph citing substantial doubt about the ability to continue as a going concern.

• 72,327,320 common shares outstanding as of September 30, 2026; no preferred shares outstanding. Common stock closed at $1.98 on October 23, 2026.

Use of proceeds and capital allocation

• Net proceeds are intended to fund the planned Phase 3 sabirnetug trial, working capital, capital expenditures and general corporate purposes; management retains broad discretion over allocation.

• Proceeds may also support complementary investments, acquisitions or in-licenses; pending use, funds are intended for investment-grade, interest-bearing securities.